China joins COVAX initiative.
The Chinese government recently announced that it has joined the World Health Organization (WHO)’s global COVID-19 initiative, COVAX.
China with its COVID-19 vaccine manufacturing capabilities will help prioritize supplying to developing countries when vaccines are ready to ensure that there is equal access to the vaccines.
Through COVAX, WHO aims to deliver at least 2 billion doses of vaccines by the end of 2021.
China’s COVID-19 vaccine candidate shows promising results.
A Chinese COVID-19 vaccine candidate, developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences appears to be safe in an early-stage clinical trial.
In the clinical trial, 191 participants aged between 18 and 59 were enrolled and vaccinated. The results showed no severe adverse reactions.
The most common adverse reactions reported by the trial participants were mild pain, slight fatigue and redness, itching, and swelling at the injection site. The candidate also induced an immune response.
The European Union purchases Johnson & Johnson’s COVID-19 vaccine candidate.
The European Union has recently sealed a deal with Johnson & Johnson to supply up to 400 million doses of its potential COVID-19 vaccine.
This is their third advance purchase contract after deals with AstraZeneca and Sanofi, bringing the number of doses secured by the EU for its population of 450 million to 1.1 billion.
Under the terms of the deal, the 27 EU states will be able to order up to 400 million doses of the potential vaccine after it is authorized by the EU medicine regulator.
The EU made an undisclosed down payment to Johnson & Johnson to secure the vaccines. They also added that they plan to allocate up to 500 million additional doses to developing countries.